Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cardiovascular and metabolic risk in patients with chronic myeloid leukemia in chronic phase receiving first-line BCR-ABL1 tyrosine kinase inhibitors in the United States: Baseline and six-month follow-up results from a prospective real-world observational study
    Meeting Abstract

    Mauro, M. J.; Oehler, V. G.; Thompson, J. E.; McCloskey, J. K.; Heinrich, M. C.; Dakhil, S. R.; DeGutis, I.; Tabano, D.; Khan, W.; Moslehi, J. J.
    Blood (2020)

    Fulltext@MSK | Save
  • LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Mato, A. R.; Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Lech-Marańda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A once daily, oral, triple combination of BTK inhibitor, mTOR inhibitor and IMiD for treatment of relapsed/refractory Richter's transformation and de novo diffuse large B-cell lymphoma
    Meeting Abstract

    Mato, A. R.; Schuster, S. J.; Foss, F. M.; Isufi, I.; Kothari, S. K.; Ding, W.; Brander, D. M.; Sitlinger, A.; Rosenthal, A. C.; Leis, J. F.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A clinical practice comparison of overall survival, time-to-next-treatment, and time-to-treatment-discontinuation among CLL/SLL patients receiving first-line ibrutinib with and without a del(17p) mutation
    Meeting Abstract

    Mato, A.; Tang, B.; Azmi, S.; Yang, K. R.; Stern, J. C.; Hedrick, E.; Huang, J.; Sharman, J. P.
    Blood (2020)

    Fulltext@MSK | Save
  • Real-world prognostic biomarker testing, treatment patterns and dosing among 1461 Patients (pts) with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the informCLL prospective observational registry
    Meeting Abstract

    Mato, A. R.; Barrientos, J. C.; Sharman, J. P.; Brander, D. M.; Gutierrez, M.; Kadish, K.; Arango-Hisijara, I.; Upasani, S.; Han, J.; Huang, Q.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Loss of LKB1/(STK11) facilitates leukemic progression of the myeloproliferative neoplasms
    Meeting Abstract

    Marinaccio, C.; Suraneni, P. K.; Celik, H.; Volk, A.; Wen, J. Q.; Ling, T.; Lasho, T.; Koche, R. P.; Famulare, C.; Stein, B. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • TET2 and DNMT3A mutations exert divergent effects on DNA repair and sensitivity of leukemia cells to PARP inhibitors
    Meeting Abstract

    Maifrede, S.; Le, B. V.; Nieborowska-Skorska, M.; Golovine, K.; Sullivan-Reed, K.; Dunuwille, W. M. B.; Nacson, J.; Hulse, M.; Caruso, L. B.; Gazze, Z.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A TCR mimic antibody-directed CAR T cell specific for intracellular NDC80 is broadly cancer reactive and displays high activity against hematological malignancies
    Meeting Abstract

    Klatt, M. G.; Yang, Z.; Liu, J.; Korontsvit, T.; Mun, S. S.; Peraro, L.; Gardner, T. J.; Bourne, C.; Dacek, M. M.; Dao, T.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of ponatinib (PON) in patients with chronic-phase chronic myeloid leukemia (CP-CML) who failed one or more second-generation (2G) tyrosine kinase inhibitors (TKIs): Analyses based on PACE and OPTIC
    Meeting Abstract

    Kantarjian, H. M.; Deininger, M. W.; Abruzzese, E.; Apperley, J.; Cortes, J. E.; Chuah, C.; DeAngelo, D. J.; DiPersio, J. F.; Hochhaus, A.; Lipton, J. H.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • COVID-19 impact on lymphoma patients' clinical outcomes - An observational cohort study
    Meeting Abstract

    Ip, A.; Mato, A.; Intrator, J.; Howard, N. P.; Petrillo, A.; Vicioso, R.; Sebti, R.; Cicogna, C.; Magarelli, G.; Leslie, L. A.; more...
    Blood (2020)

    Fulltext@MSK | Save